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Abstract
Background: Comparative genomic hybridization microarrays for the detection of constitutional
chromosomal aberrations is the application of microarray technology coming fastest into routine
clinical application. Through genotype-phenotype association, it is also an important technique
towards the discovery of disease causing genes and genomewide functional annotation in human.
When using a two-channel microarray of genomic DNA probes for array CGH, the basic setup
consists in hybridizing a patient against a normal reference sample. Two major disadvantages of this
setup are (1) the use of half of the resources to measure a (little informative) reference sample and
(2) the possibility that deviating signals are caused by benign copy number variation in the "normal"
reference instead of a patient aberration. Instead, we apply an experimental loop design that
compares three patients in three hybridizations.
Results: We develop and compare two statistical methods (linear models of log ratios and mixed
models of absolute measurements). In an analysis of 27 patients seen at our genetics center, we
observed that the linear models of the log ratios are advantageous over the mixed models of the
absolute intensities.
Conclusion: The loop design and the performance of the statistical analysis contribute to the
quick adoption of array CGH as a routine diagnostic tool. They lower the detection limit of
mosaicisms and improve the assignment of copy number variation for genetic association studies.
Background
Array Comparative Genomic Hybridization (array CGH)
[1,2], also called molecular karyotyping [3], detects copy
number aberrations and variations at high resolution on
a genomewide scale [4,5]. Genomewide array CGH has
been applied to detect chromosomal imbalances in
patients with congenital anomalies and mental retarda-
tion [6-12]. An illustrative example is presented in Figure
1. Array CGH is a highly effective technique that is enter-
ing routine clinical use much faster than other microarray
technologies. Indeed, compared to, for example, expres-
sion microarrays, array CGH enjoys several technical
advantages: (1) genomic DNA samples are less prone to
degradation than mRNA samples, (2) genomic DNA sam-
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ples show much less variation between biological repli-
cates than mRNA samples, and (3) interpretation of
chromosomal imbalances is much easier than that of
expression fingerprints. These advantages explain why
array CGH for the diagnosis of constitutional anomalies is
progressing faster towards the clinic than expression
microarrays for the prediction of clinical outcome (e.g., in
cancer), for which a few applications are now entering
clinical practice [13-15].
Array CGH mostly competes with and is complementary
to conventional karyotyping and Fluorescent In Situ
Hybridization (FISH). Compared to conventional karyo-
typing, it offers a resolution between 10 kb and 1 Mb,
instead of about 5 Mb, and detects at least twice as many
aberrations [12]. Furthermore, it does not require the use
of metaphase chromosomes, which makes it faster and
less labor intensive. However, current array CGH tech-
niques cannot detect balanced translocations, while this is
straightforward with conventional karyotyping. Com-
pared to FISH, array CGH provides genomewide coverage,
instead of covering only a limited set of probes--so, it does
not require prior knowledge of which aberration might be
present (based on the phenotype of the patient).
The most frequent experimental setup for array CGH con-
sists in comparing genomic DNA of a patient (test) with
that of a normal individual (reference) using a two-chan-
nel microarray consisting of DNA segments spread across
the whole genome. In the case of our clinical platform, the
DNA segments consist in PCR-amplified BAC clones.
However, the discussion applies equally to spotted long
oligo platforms. So, we will refer to our probes as reporters.
DNA from the test and reference samples is extracted,
labeled with different fluorescent dyes (usually Cy3 and
Cy5), hybridized to the microarray, and then scanned by
two-channel laser scanner. Aneuploid chromosomal
regions are detected as probes with a deviant log ratio of
the intensities of the test against reference signal (approx-
imately log2(1/2) for a deletion and log2(3/2) for a dupli-
cation). Usually the experiment is repeated in a dye-swap
with the uorescent labeling of test and reference
exchanged. The signals are then averaged over the dye-
swap replicates to reduce the signal-to-noise ratio.
An alternative design [10] is a loop design in which three
hybridizations are carried out with three test patients that
are compared with each other: Patient 1 versus Patient 2,
Patient 2 versus Patient 3, and Patient 3 versus Patient 1,
as shown in Figure 2. This design measures the intensities
of three test samples in a statistically balanced way and
requires no normal reference sample. Hence, only three
arrays are used to analyze three patients and to obtain two
measurements for each of them. For the classical dye-swap
design, half of the resources are consumed to measure the
reference sample of a normal individual and, therefore,
BAC-based Array CGH Figure 1
BAC-based Array CGH. Wolf-Hirschhorn syndrome was discovered in 1961 by Herbert Cooper and Kurt Hirschhorn. The 
phenotypical features include mental retardation, distinct facial appearance (typical Greek warrior helmet faces, high forehead), 
and seizures. Wolf-Hirschhorn is characterized by a deletion of the end of the short arm of chromosome 4; in particular, a 
deletion of the terminal band (4p16.3) is essential for full expression of the phenotype. Wolf-Hirschhorn can be detected with 
array CGH by comparing a genomic DNA sample of the patient (test) with that of a normal individual (reference). DNA 
extracted from test and reference sample is labeled with different fluorescent dyes (typically Cy3 and Cy5) and hybridized to 
the microarray. Array CGH probes can be PCR-amplified Bacterial Artificial Chromosomes or BAC clones or spotted long oli-
gos. The microarray is scanned by two-channel laser scanner and aneuploid chromosomal regions are detected as probes with 
a deviant log ratio. This example clearly indicates a deviation of the log ratios at the end of the short arm of chromosome 4 and 
allows to confirm the hypothesis of Wolf-Hirschhorn syndrome.BMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
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six arrays would be necessary to obtain as many measure-
ments from the test samples.
Extensive genomic variation (called copy number varia-
tion (CNV)) is also present in normal individuals [16-18].
The extent of this variation is surprising (covering at least
10% of the genome) and likely to have major implica-
tions for human variation and disease. In the classical dye-
swap design, a deviant log ratio for one reporter in the test
sample could just as well be associated with a variation in
the reference sample. The difficulty in disambiguating
deviations between the test and reference sample prevents
us also from replacing the reference sample with a second
test sample in the dye-swap design. The loop design, on
the contrary, unambiguously associates a deviation to the
correct sample by looking for a unique pattern of log
ratios. For example, a duplication in Patient 1 will be asso-
ciated approximately to a positive log ratio in the Patient
1 vs. Patient 2 hybridization, a negative log ratio in the
Patient 3 vs. Patient 1 hybridization, and a null log ratio
in the Patient 2 vs. Patient 3 hybridization. No deletion or
duplication in another patient will display the same pat-
tern, so the association is unambiguous. Another way to
elevate this issue in dye swap experiments would be to use
a DNA sample, pooled from several individuals. However,
for frequently occurring CNVs, the intensity ratios will be
reduced and, therefore, pooling will rather complicate
data interpretation instead of simplifying [10].
For the statistical analysis, we consider two approaches for
array CGH: linear modeling of the log ratios and mixed
modeling of the absolute signal intensities. We compare
both methods on a test data set consisting of 27 patients
(9 loop designs) and we implement the method with the
best signal-to-noise ratio as a user-friendly web applica-
tion. Both methods analyze the data in a clone by clone
way. On high resolution arrays, the resulting estimates can
however be used as input for segment wise analysis tech-
niques. Experimental designs that make the best use of
available resources are essential for the widespread adop-
tion of array CGH as a routine clinical tool for the diagno-
sis of constitutional chromosomal aberrations. Reduction
of false positives and negatives guarantees the best service
to the patient and the best use of economic resources,
which are key factors in a clinical environment. Further-
more, correct assignment of "benign" copy number varia-
tions to the right sample will be important in upcoming
studies of association between copy number variations
and disease. Finally, this design will also lower the detec-
tion limit for mosaicism (i.e., chromosomal aberrations
present in only a percentage of the cells).
Array CGH for the detection of congenital chromosomal
aberrations is also a key method for the genomewide dis-
covery of gene function. Patients with chromosomal aber-
rations provide a natural form of forward genetics screen.
Through genotype-phenotype correlations, phenotypes
can be associated to chromosomal regions containing
only a few to a few tens of candidate genes [19]. Further
prioritization of candidate genes using bioinformatics
approaches and validation in small animal models (for
The loop design Figure 2
The loop design. Schematic overview of a reference and a loop design, in which three patients are compared. In the refer-
ence design, the three patients are compared to the DNA of a normal individual (reference). In the loop design the three 
patients are compared two-by-two.BMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
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example, zebrafish or fruit fly) allows rapid identification
of disease causing genes [20].
Results and Discussion
New statistical models for the analysis of loop designs for 
array CGH
Two main philosophies vie for dominance for the statisti-
cal modeling of microarray signal intensities: (1) linear
models of log ratios of intensities and (2) mixed models
of absolute intensities. Two-channel microarrays were
originally developed so that taking the ratio between the
Cy3 and Cy5 intensity of a spot would eliminate multiple
sources of variations (in particular, the amount of DNA
material per spot). Linear models of log ratios keep in
track with this philosophy and extend it by observing that
log ratio measurements from different hybridizations
containing equivalent samples are interdependent. They
formulate these dependencies as a set of linear relations
that are then inverted to obtain tighter estimates for a
smaller set of independent statistical effects (which
remain in essence similar to log ratios). By contrast, mixed
models of absolute intensities aim at disentangling the
signals from the Cy3 and Cy5 channels by expressing the
intensities as the sum of an extensive set of fixed and ran-
dom effects dependent on many factors that systemati-
cally affect the microarray measurements (dye effect, array
effect, spot effect, etc.). Although the mixed models we
consider are linear mixed models and thus also linear
models, we will for simplicity refer in this paper to the two
classes of methods as being "linear models" vs. "mixed
models", respectively.
Mixed model of absolute signal intensities
We will apply a mixed model as proposed by [21]. These
models were originally applied to cDNA microarrays, but
they can be tailored to the analysis of array CGH. Before
applying a mixed model, we want to correct hybridization
signals for possible spatial effects (which cannot be easily
corrected with the mixed model). We therefore apply a 2D
spatial loess correction to the hybridization intensities
and obtain loess corrected log ratios, from which we can
derive corrected intensities. The mixed models proposed
by [21] consist of two successive models: the normaliza-
tion and the reporter-specific model. The normalization
model corrects for array, dye, and patient effects. The fit-
ted model can be written as ycij = μ+ Pi + Aj + PAij + rcij,
where ycij are the Cy3 and Cy5 intensities for Clone c,
Patient i, and Array j, μ is the overall average, Pi is the fixed
patient effect with three levels (i = Patient 1, 2, or 3), Aj
estimates the random array effect (also with three levels j
= Array 1, 2, or 3), and PAij fits the interaction effect
between the patient and array effect, and in this way it also
corrects for the dye effect. For each reporter, we extract the
residuals  rcij  from the normalization model and fit a
reporter-specific model rcij = Cc + CPci + CAcj +εεcij, where
rcij  are the residuals obtained from the normalization
model, Cc is the overall average for Reporter or Clone c,
CPci is the fixed patient effect for Reporter c with three lev-
els (i = Patient 1, 2, or, 3), CAcj estimates the random array
effect for Reporter c (also with three levels j = Array 1, 2,
or 3), and εεcij fits the random error effect. Our main inter-
est is in the estimates of the CPci effects, which reflect the
difference between the patients for Reporter c. Specifically,
we assess whether the contrasts Patient 2 vs. Patient 1 (=
CPc2 - CPc1) and Patient 1 vs. Patient 3 (= CPc1 - CPc3) are
equal to zero with a Wald's F-test. In the case where the
contrast is significantly larger than zero for a chosen sig-
nificance level α, we call this contrast positive. In the case
where it is smaller than zero, it is called negative. Else we
assign 0. Based on both hypothesis tests, the reporters are
classified as duplicated or deleted according to the classi-
fication shown in Table 1. For example, if the contrast
Patient 1 vs. Patient 3 (= CPc1- CPc3) is positive and the
contrast Patient 2 vs. Patient 1 (= CPc2- CPc1) is negative
for a reporter, then this reporter is likely to be duplicated
for Patient 1. In some rare cases, we obtain as result a
reporter that has, for example, a negative value for both
contrasts CPc1 CPc3 and CPc2 CPc1, which is none of the
combinations in Table 1. In this case, we call the reporter
strange.
Linear model of log ratios
An alternative statistical tool is a linear model of the log
ratios, as proposed by [22]. In contrast to the mixed
model, this technique fits the 2D spatial loess corrected
log2 ratios directly. In this particular case, we can choose
the following contrasts Cc1  = log2(Pc1/Pc3) and Cc2  =
log2(Pc2/Pc1), where Pci corresponds to the true underlying
signal for Reporter c for Patient i. These contrasts corre-
spond to the samples that were directly compared on the
first two slides in Figure 2 and the observed log ratios on
these slides should on average be equal to the contrast.
The data of the third slide should then correspond on
average to Cc3 = log2(Pc3/Pc2) = Cc1-Cc2. The linear model
that fits the data can be written as
where E denotes the expectation of a random variable, X
is the matrix of linear dependencies, Cc is the vector of
contrasts for Reporter c, and yci denotes the log2 ratio for
Reporter c measured on the ith slide. For each reporter, the
least squares estimates of the three contrasts are obtained.
To classify the contrasts as significantly duplicated,
deleted, or not changed in copy-number, we apply the
moderated t-statistic as implemented in the Bioconductor
package  limma, which implements linear models for
microarray data analysis [22]. The p-values from the mod-
erated t-test were corrected to control the false discovery
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rate with Benjamini-Hochberg [23]. Similarly to the
mixed model, we can detect reporters that are duplicated
or deleted for a patient, based on the p-values of the con-
trasts. For a chosen cut-off value α, we decide whether a
reporter is not differentially expressed (0), upregulated
(positive), or downregulated (negative) for a contrast.
Based on the two contrasts, we can again classify a reporter
as duplicated or deleted for a patient according to Table 1.
Again, we can on rare occasions obtain strange reporters.
Model validation
The mixed model and linear model provide two distinct
ways to analyze the loop design experiments. To decide
which method is preferable, we will first check which esti-
mation method best separates the aberrant from the non-
aberrant reporters. This will already give an indication to
which method is preferred. Secondly, we will compare the
false positive and false negative rates for a number of cut-
off values α. Based on this information, we will decide
which method to use and choose a cut-off value to call a
reporter significantly duplicated or deleted. For the com-
parison of the analysis approaches, we consider a data set
consisting out of nine loop designs from patients seen at
our genetics center (Center for Human Genetics, U.Z.Leu-
ven; see Table 2 and Methods section). Fifteen of the 27
patients involved in the nine loop designs showed one or
more confirmed deletions or duplications of a chromo-
somal segment. Two experiments (Experiments 1 and 9)
in our test data set include a sex mismatch. As for these
experiments, the Y chromosome is absent for at least one
of the patients, the measurements on the Y chromosome
were excluded for both experiments from all computa-
tions. Because the X chromosome has regions with chro-
mosome Y homology, the intensity ratios of chromosome
X reporters are also more variable, and hence the X chro-
mosome was also excluded from the computations for
Experiments 1 and 9. For each of the nine loop designs,
we classify the reporter as being deleted/duplicated if the
reporter was classified as deleted or duplicated for one of
the patients in the loop design. If the reporter was not
deleted/duplicated for any of the patients in the loop
design, the reporter was classified as non-aberrant. In
total, this data set comprises 328 aberrant reporters: 116
deleted and 212 duplicated reporters. Over all nine exper-
iments, we have a set of 30,668 measurements for non-
aberrant reporters for any of the three patients in the loop.
Signal-to-noise ratios
Assessing which method is best capable of distinguishing
between the intensities of aberrant and non-aberrant
reporters can be done by computing signal-to-noise-ratios
(SN) (for both deletions and duplications separately) as
where alteration type is deletion or duplication. As we
have collected a data set with 212 duplicated reporters,
116 deleted, and 30,668 non-aberrant reporters, we can
compute the SN values based on the absolute values of the
contrasts Patient 1 vs. Patient 3 and Patient 2 vs. Patient 1,
for both the linear model and the mixed model. The
results are shown in Table 3. As for deleted clones the dif-
ference between their log ratios (±  ) and log ratios of
non-aberrant clones is larger than for the log ratios
derived from duplicated clones (±  ), the signal-to-noise-
ratio is of course larger for the deleted reporters than for
the duplicated reporters. The linear model leads to a sig-
nificant reduction in the noise, especially for the non-
aberrant reporters, and this results in a larger signal-to-
SN
meanalteration type meannon-aberrant
1
2
va
alteration type =
−
r ralteration type varnon-aberrant
,
+ ()
1
2
2
3
Table 1: Classification of the reporters. 
Classification Log Ratio patient1/patient3 Log Ratio Patient2/patient1
Duplication for patient1 positive negative
Duplication for patient2 0 positive
Duplication for patient3 negative 0
Deletion for patient1 negative positive
Deletion for patient2 0 negative
Deletion for patient3 positive 0
Each reporter is classified as duplicated (positive), deleted (negative), or not changed in copy-number (0) for two chosen contrasts, i.e. Patient 1 
versus 3 and Patient 2 versus 1. Based on the results of both contrasts a reporter can be recognized as duplicated or deleted for Patient 1, 2, or 3, 
according to this scheme.BMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
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noise-ratio. Therefore, these statistics are favorable to the
linear model. True positive and false positive rate
First, we compute for a number of significance levels α,
the percentage of the duplicated and deleted reporters that
are correctly classified as duplicated and deleted, respec-
tively, in our test data set, according to both methods. The
true positive (TP) rates are shown for the mixed model
and the linear model in Figure 3 in function of the signif-
icance level α. For the linear model, the TP rate reaches a
maximum of 0.954 for significance level αα = 0.009. For
higher α, surprisingly, the TP rate drops a little. This effect
results from the fact that some reporters become strange
reporters for larger significance levels α. For the classifica-
tion with the mixed model, the TP rates grow slowly as the
significance level increases. Within this range of signifi-
cance levels α, it never reaches the maximum TP rate value
obtained with the linear model. Perhaps it comes closer to
the result obtained with the linear model if we allow for
even larger significance levels α, but this will increase the
FP rate and the number of strange reporters to an unac-
ceptable level. Outside the duplicated and deleted
regions, other reporters were also classified as duplicated
or deleted. These positives can be false positives, due to
Table 2: Loop design test data set. 
Experiment Patient Deletions/duplications length Confirmed with
1 1 deletion on 13 25 karyotyping
2 duplication of X (sex mismatch) 149 karyotyping
2 1 duplication of 18 102 karyotyping and FISH
3 1 deletion on 10 6
2 duplication on 7 20
3 duplication on 15 43
4 2 deletion on 4 15 FISH
3 Inversion (p11-q13) karyotyping
5 1 deletion on 12 14 FISH
61 d e l e t i o n  o n  9 6
3 deletion on 12 7
7 2 duplication on 5 13
2 deletion on 18 16
8 1 duplication on 13 15 FISH
1 deletion on 13 12 FISH
2 balanced translocation (2;6)(q33,1;p23) karyotyping
9 1 duplication on 7 11
1 deletion on 7 15
2 deletion of X (sex mismatch) 158 karyotyping
3 duplication on 21 8
The nine loop design experiments, listed in the table, will be used as a test data set to compare the two methods, linear model and mixed model. 
For each aberration present in the experiment the number of deleted or duplicated reporters is indicated.
Table 3: Signal-to-noise-ratios.
Mixed model Linear model
meannon-aberrant 0.00701 -0.00064
s.d.non-aberrant 0.11306 0.06914
meandupl. 0.48515 0.48777
s.d.dupl 0.12920 0.11967
SNdupl 3.93861 4.99782
meandel 0.76779 0.78468
s.d.del 0.22275 0.18787
SNdel 4.30702 5.54778
For both methods (i.e., the mixed model and the linear model), the 
number of reporters, average and standard deviation of the average 
log2-ratios are given for the non-aberrant (# = 30,668), duplicated (# 
= 212), and deleted reporters (# = 116). Based on these numbers the 
signal-to-noise-ratios are computedBMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
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technical artifacts, or they can indicate true biological var-
iations. At this point, we will not make the distinction
between both kinds of aberrant reporters, as it does not
affect the method comparison, and we will refer to this set
of positives as non-confirmed positives. At a later stage,
this set of non-confirmed positives will be examined in
depth, for one method and one significance level α. The
number of these non-confirmed positives is shown in Fig-
ure 4. The figure shows that there is no clear difference in
the non-confirmed positive rates between both methods.
For low significance levels α  the linear model has a
slightly smaller number of non-confirmed positives. The
combined results on the signal-to-noise ratio, the TP, and
non-confirmed positive rate lead to the conclusion that
the linear model is the preferable method.
Optimization of the linear model
In the previous section, we focused on how well the differ-
ent methods fit the measurements by assessing their capa-
bilities to divide the non-aberrant reporters from the
deviating reporters and by comparing the FP and TP rates.
This indicated that the linear model was best suited to dis-
tinguish these groups of reporters, although also the linear
model has a fairly high FP rate. However, we did not yet
benefit from all available information.
Completely and partially deleted reporters
To further optimize the reporter classification, we will use
the fact that if, for example, a reporter of Patient 1 is
deleted or duplicated, its contrast Patient 2 vs. Patient 1
should theoretically be equal to log2 ()  =  1  o r  l o g 2 ()
= -0.58, respectively. However, nonlinear saturation
effects in the signals cause a deviation from these values.
Instead of taking the theoretically expected values (i.e., ±
1 and ± 0.58), we will estimate the expected values based
on the linear model estimates of the contrasts for the
group of confirmed deletions and duplications, after
exclusion of the deletions and duplications on the X and
Y chromosome. This results in an average for the absolute
log ratios of 0.86 for the deleted reporters and 0.54 for the
duplicated reporters. Therefore, if we detect with the lin-
ear model a reporter that is likely to be duplicated or
deleted, we extract its contrasts Cc1 and Cc2. If their abso-
lute value is not larger than 0.54 or 0.86, respectively, we
use an adapted version of the moderated t-test, as imple-
mented in the limma package. We use the same standard
deviation of the contrasts, as computed within the previ-
ous limma procedure, and test one-sidedly the hypothesis
H0 : |C| = 0.54 versus Ha : |C| < 0.54 for the duplicated
reporters and H0 : |C| = 0.86 versus Ha : |C| < 0.86 for the
deleted reporters. If we cannot reject the hypothesis at a
significance level αpartial for both tests, we call the reporter
completely deleted or duplicated, else we call the reporter
partially deviating (i.e., only a part of the clone has been
deleted/duplicated instead of the complete clone). As a
significance level, we choose αpartial = 0.01. For this signif-
icance level, the non-confirmed positives restricted to the
reporters that are completely deleted are plotted as a blue
line in Figure 4. This non-confirmed positives rate ranges
between 0.001 and 0.002.
The non-confirmed positives
The non-confirmed positives rate obtained in the previous
section is not a direct indication of the false positives rate,
as they can comprise not only false positives, but also
both true positives or polymorphic reporters. In our data
set of nine loops, we saw that after extraction of clones
that were proven to be copy number variable regions, 15
single clones with complete deletions or duplications are
picked up by our method, at a significance level of αα=
0.001. Seven of these clones have been previously
described as polymorphic [24]. One clone (RP1-93N13)
overlaps with a CNV present in the normal population
(Genomic Database of Variants; http://projects.tcag.ca/
variation/). To determine whether the remaining report-
ers are false positives or true CNVs, qPCR or FISH [10] was
performed. For six clones, the deletion or duplication was
confirmed. For one clone we could not determine the
copy number variation due to lack of DNA. The remaining
four clones were all measured in Experiment 1 and caused
2
1
2
3
True positive rate Figure 3
True positive rate. For a range of significance levels α, we 
compute the true positives rate (TP) for both the mixed 
model and the linear model. These true positive (TP) rates 
(y-axis) are plotted against the significance levels α (x-axis) 
and connected with a green line for the mixed model and a 
red line for the linear model.
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by low spot quality, as they had a large discrepancy
between the mean and the median pixel intensities and a
large standard deviation of the pixel intensity. Hence, our
method reliably detects aberrant clones. An overview of
these results is shown in Table 4.
At  αα= 0.001, also 13 clones were classified as being
strange. Ten of these clones overlapped with CNVs that are
present in the normal population, according to the
Genomic Database of Variants. (Note also that not all nor-
mal CNVs have already been identified.) Therefore, we
suspect that a strange clone can often be explained as a
polymorphic clone that is shared by two patients. Taken
together these results indicate that at α = 0.001 our proce-
dure has both low false negatives (TP rate around 95%)
and essentially no false positives for completely deleted or
duplicated clones. Most clones detected as positive or
strange outside the regions known in the benchmark have
been confirmed by qPCR or FISH; several of them being
known normal CNVs.
Web application
The method is implemented as a web application and is
available at http://www.esat.kuleuven.be/loop. A demo
account with test data is available. Currently, the applica-
tion and the statistical analysis have been tested and
refined on an in-house series of over 400 patients. Details
on the implementation and the use of the web application
can be found in Additional file 1.
Conclusion
A first point of discussion is to which platforms the pro-
posed statistical models are applicable. Some array CGH
platforms are available using single-channel microarrays.
In this situation, the loop design is simply not applicable.
The loop design is directly dependent on using a two-
channel microarray.
A second point of discussion is a main assumption that
underlies our analysis, that two patients never share the
same aberration. If two patients have an aberration for the
same reporter, the statistical model cannot correctly inter-
pret the result|resulting mostly into a strange reporter. For
the detection of congenital anomalies, this effect is pre-
vented by putting into a loop design patients who have
clearly distinct phenotypic patterns. The rare cases where
a common aberration is still present can be rescued at the
validation stage. Incorrect assignment to the third patient
would not be validated by FISH or qPCR and, in this case,
the possibility of a common aberration for the two other
patients should be kept in mind. Reporters flagged as
strange can be validated in all three patients to clear out
the situation.
At our genetics center, the pick-up rate (i.e., the percentage
of patients that show an chromosomal aberration) is
around 20%. Hence, a loop design consisting out of three
patients with a CNVs occurs only in one out of 125 cases.
The likelihood of having patients that share an abnormal-
ity is even smaller. However, this assumption is unrealistic
when studying tumors or when doing preimplantation
diagnosis. In the case of tumors, many chromosomal
regions can be affected and overlap between patients is
essentially unavoidable. In the case of preimplantation
diagnosis, we have developed a procedure where one of
the eight blastomere cells of an 8-cell embryo from in vitro
fertilization is assessed by single-cell array CGH [25]. In
this procedure it is essentially impossible to guarantee
that the aberrations from different blastomeres do not
overlap (for example, some aberrant embryos have cha-
otic genomes where many chromosomes are affected).
In some rare cases, deviating reporters cannot be assigned
as duplicated or deleted, but are instead labeled as strange.
We observed that the majority of these strange reporters
corresponded to polymorphic reporters. This can corre-
spond to the situation where two patients share a complex
polymorphic reporter [16] and will be investigated more
deeply in a subsequent study.
Our analysis was characterized by the fact that for our
optimized threshold we have a low number of false nega-
tives and close to no false positives. Given that a second-
ary validation is available through FISH, which can catch
false positives but not false negatives, we would want to
increase our threshold further to decrease the number of
false negatives at the cost of a few false positives that can
then be caught by the FISH validation. However, increas-
ing the threshold further results rather in more reporters
being labeled as strange, which we prefer to avoid.
At a significance level of 0.001, for 0.251% of the clones
the intensity ratios were suggestive of partial deletions of
duplications. Most likely, the intermediate intensity ratios
reflect the presence of subclonal CNVs (i.e., only a part of
the clone has been deleted/duplicated instead of the com-
plete clone). Recently, several articles show high levels of
small CNVs in the human genome [16-18,26]. Moreover,
we performed qPCRs on some of these clones using sev-
eral PCR primers and could confirm such partial deletions
(data not shown). However, since no systematic analysis
of all these clones has been performed, we do not know
the number of false positives.
In our specific setting and in our hands, linear models
clearly outperformed mixed models. We do not draw any
conclusion with regard to the suitability of one class of
method versus the other in general. In our setting, weBMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
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hypothesize that the mixed model was less robust to devi-
ation from the underlying normality assumptions or that
the more compact (fewer parameters) estimation proce-
dure of the linear model increased its robustness. The
improvement of the mixed model in this setting appears
to be an interesting research direction.
Microarray CGH for the diagnosis of congenital chromo-
somal aberrations is progressing rapidly from the research
lab to the clinic. What value do such improved statistical
procedures add to the diagnosis? First of all, increasing the
signal-to-noise ratio between aberrant and normal clones
through our statistical procedure is likely to improve the
detection of low-grade mosaicism (i.e., chromosomal
aberrations present in only a percentage of all cells),
which is currently difficult to detect by array CGH. In a
previous study [25], we presented a power analysis model
for the detection of low-grade mosaicism where the sig-
nal-to-noise ratio was a critical factor in determining the
limit of detection for mosaicism.
Secondly, CNVs are hard to assign with certainty to the
patient instead of the "normal" reference. While these
CNVs are currently largely handled as noise, some of them
are likely to act as genetic modifiers that are risk factors for
disease or modulate its penetrance and phenotypic spec-
trum [16]. Association studies are currently being started
to evaluate the importance of such CNVs in both congen-
ital and acquired disorders. Unambiguous assignment of
the "normal" CNVs to the correct sample is therefore par-
amount. And as a last point, there is the issue of cost per
experiment. To keep cost down, some laboratories do not
perform a dye swap when using the basic array CGH setup
(patient vs. normal reference). In this case, a single array
is used per patient. However, only one measurement per
patient will be available in this case instead of two with
our design, which means a higher level of false positives
and negatives. False positives will be caught by the sec-
ondary FISH or qPCR validation, but false negatives will
not. This results in lower quality diagnostics for the
patient.
In conclusion, our results indicate that the experimental
loop design, together with a statistical analysis by a linear
model, provides an efficient procedure for the detection of
chromosomal aberrations in congenital anomalies by
array CGH. It is significantly superior to the classical setup
by doubling the use of resources and unambiguously
assigning variation to the correct patient. These improve-
ments have a direct impact on the diagnosis offered to the
patient using the microarray technology that is closest to
routine clinical use.
Methods
Array CGH
A 1 Mb resolution BAC array was performed as described
in [10]. In short, 3500 BAC en PAC clones from the Wel-
come Trust Sanger Institute were amplified by two rounds
of DOP-PCR [27]. The purified aminolinked PCR prod-
ucts were spotted in duplicate on 3-D CodeLink Bioarray
System slides (Amersham Biosciences, Piscataway, NJ).
150 ng of patient DNA was labeled by random prime
labeling system (BioPrime Array CGH Genomic Labeling
System, Invitrogen) using Cy3- and Cy5-dCTPs (Amer-
sham Biosciences). Probe concentration and labeling effi-
ciencies were measured using the nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Rockland,
DE). The probe was placed on the slide under a glass cover
slip (24 × 24 mm). The slides were incubated for 42-72
hours at 37°C under humified conditions.
Post hybridization washing was performed by soaking in
1 × PBS for 10 minutes and followed by a stringency wash
on 42°C for 30 minutes in 50% formamide 2× SSC solu-
tion and 10 minutes in 1× PBS at room temperature. To
finalise, the slides were dried by centrifugation for at least
1 minute.
Image and data analysis
After the washing, a two-channel scan was performed with
an axon laser scanner GenePix 4000B (Molecular Devices,
Union City, CA) at 532 nm and 635 nm using GenePixPro
6.0 program. The results are converted into GPR format
and can be directly uploaded to the web-based applica-
tion. The median spot intensities were corrected with the
local median background, and only those spots with a sig-
False positive rate Figure 4
False positive rate. For the mixed model and the linear 
model, the false positive (FP) rates are plotted for the range 
of significance levels α with a green and red line, respectively. 
The FP rate for the complete deletions or duplications, 
obtained via the linear model is indicated in blue.
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nal above background (i.e., foreground intensity larger
than local background intensity plus twice the local stand-
ard deviation of the background) were retained for the
analysis. In this way, only few spots are lost, as almost all
spots are above background (on average 96.6%). The
ratios of the Cy5 to the Cy3 intensities were computed for
each reporter and base 2 log transformed. The log ratios
are normalized using a 2D spatial loess normalization, in
which one applies a loess regression to fit the log2-ratios
(M-values) on the coordinates on the slide as predictor
variables.
Benchmark data set
For the comparison of the analysis approaches, we con-
sider a data set consisting out of nine loop designs or 27
patients with mental retardation (MR) and multiple con-
genital anomalies (MCA). The patients were seen at our
genetics center (Center for Human Genetics, U.Z.Leuven).
Conventional karyotyping showed chromosomal imbal-
ances in 11 patients. Analysis of the patients was carried
out with a 1 Mb BAC array. In first instance, the data anal-
ysis strategy that we had previously developed was
applied to this data. In this procedure, a region is called
Table 4: The non-confirmed positives. 
Clone Status Validation method
RP11-114K7 [24]
RP11-161M6 [24]
RP1-225D2 [24]
RP6-14C6 [24]
RP11-342F21 [24]
RP11-342F21 [24]
RP6-22D12 [24]
RP1-93N13 Genomic Database of Variants
RP11-2P5 Single clone deletion qPCR
RP11-48E16 Single clone deletion qPCR
RP11-127A9 Single clone deletion qPCR
RP11-469N6 Single clone deletion qPCR
RP11-576I16 Single clone duplication qPCR
RP11-152O18 Single clone deletion FISH
RP11-361M10 Not confirmed Lack of DNA
RP11-404P12 Low spot quality
RP5-982E9 Low spot quality
RP11-301H15 Low spot quality
RP4-742J24 Low spot quality
Outside the duplicated and deleted regions, 15 reporters were also classified as being completely duplicated or deleted. Eight of them could be 
confirmed as being polymorphic clones according to [24] and the Genomic Database of Variants. Six of them confirmed with FISH or qPCR. One 
clone could not be confirmed, due to lack of DNA.BMC Bioinformatics 2009, 10:380 http://www.biomedcentral.com/1471-2105/10/380
Page 11 of 12
(page number not for citation purposes)
aberrant, if one clone passes the threshold of 4 × SD and
if two or more flanking clones were passing the threshold
of log2 ( ) - 2 × SD as described in [24]. If a deletion or a
duplication larger then 3 Mb was detected, FISH was per-
formed to confirm the results of the array. In case of a
duplication smaller than 3 Mb, we performed quantitative
PCR (qPCR) [10]. 16 out of 27 patients show one or mul-
tiple clone anomalies, whereas 10 patients are apparently
normal, at least according to the results of the array. One
of the patients was a carrier of an inversion and another
patient had a balanced translocation. Both aberrations
cannot be detected by array CGH, but with conventional
karyotyping; as such these patients did not contribute data
to the benchmark. A short summary of the data set is
shown in Table 2. In total, this data set comprises 635
aberrant clones: 274 deleted and 361 duplicated clones.
The study was approved by the institutional review board
and appropriate informed consent was obtained from
human subjects. The data set has been uploaded to the
Gene Expression Omnibus (Accession number GSE6538)
and is publicly available.
Consent
Written informed consent was obtained from the patient
for publication of accompanying images. A copy of the
written consent is available for review by the Editor-in-
Chief of this journal.
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